Showing 15 posts of 31 posts found.


Amgen biosimilar proves non-inferior to J&J’s Remicade in rheumatoid arthritis

June 27, 2018
Research and Development, Sales and Marketing Amgen, Johnson & Jonson, Remicade, pharma, rheumatoid arthritis

Amgen has unveiled new Phase 3 data for its biosimilar version of Johnson & Johnson’s Remicade (infliximab), confirming that it …


Novartis’ Sandoz scores EU approval for Remicade biosimilar

May 24, 2018
Sales and Marketing EU, Europe, Novartis, Remicade, Sandoz, Zessly, pharma

The European Commission has given its approval to Sandoz, Novartis’ generics and biosimilars unit, for its biosimilar version of Janssen’s …


US court upholds ruling that J&J’s Remicade patent is invalid

January 24, 2018
Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Remicade, biosimilars, infliximab, patent, pharma

The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis …

What will Pfizer do with its second Remicade biosimilar?

December 14, 2017
Sales and Marketing Ixifi, Johnson & Johnson, Pfizer, Remicade, biosimilars, biotech, drugs, inflectra, pharma, pharmaceutical

Pfizer is now in the unusual position of owning two biosimilars to Johnson & Johnson’s Remicade, though one of these …


Switching Crohn’s patients to biosimilar Inflectra from Remicade is safe and effective, Pfizer says

October 30, 2017
Research and Development, Sales and Marketing Crohn’s disease, Pfizer, Remicade, crohn's disease, inflectra, pharma

Pfizer has released new data on its Crohn’s disease (CD) treatment Inflectra (infliximab CT-P13) which indicate that switching patients to …


MSD under CMA investigation over unfair Remicade pricing

May 24, 2017
Research and Development, Sales and Marketing Competition and Marketing Authority, MSD, Remicade

MSD is facing legal trouble after the Competition and Marketing Authority (CMA) alleged that the pharmaceutical firm had engaged in …


J&J launches lawsuit to block release of Remicade biosimilar

May 19, 2017
Medical Communications, Sales and Marketing J&J, JJ, Remicade, Samsung Bioepis

Samsung Bioepis gained approval to launch its biosimilar to Johnson & Johnson’s Remicade just last month, on 21 April, but …


Pfizer’s Remicade biosimilar displays similar efficacy

February 22, 2017
Research and Development Johnson & Johnson, Pfizer, Remicade, inflectra

Pfizer and Celltrion have announced new data for their Remicade biosimilar, Inflectra, that shows that the drug is comparable in …


Pfizer sets release date for rival to J&J’s blockbuster drug

October 18, 2016
Manufacturing and Production J&J, JJ, Johnson & Johnson, Pfizer, Remicade, inflectra

Pfizer have announced that they will begin shipping their rival to Johnson & Johnson’s Remicade by the end of November. …


J&J loses Remicade patent fight, pledges to continue fight against biosimilars

August 18, 2016
Research and Development, Sales and Marketing Johnson and Johnson, Remicade, biosimilar, biosimilars, infliximab, patent

Johnson and Johnson has announced that it has lost in a patent dispute between biosimilar makers Celltrion and Hospira, relating …


New data on biosimilars of the big three anti-TNF drugs presented at EULAR 2016

June 8, 2016
Research and Development, Sales and Marketing Benepali, Biogen, Enbrel, Flixabi, Humira, Remicade, Samsung Bioepis, biosimilars, eular 2016, sb5

Samsung Bioepis has presented data at EULAR 2016 on three biosimilars of the highly selling anti-TNF drugs Remicade (infliximab), Enbrel …


Samsung Bioepis’ Remicade biosimilar set for CHMP verdict

March 31, 2016
Medical Communications, Sales and Marketing Flixabi, Remicade, Samsung Bioepis, biosimilars, infliximab

Samsung Bioepis has confirmed that the European Commission’s scientific committee, the CHMP, is this week discussing the approval of its …

Latest content